Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Healthcare Pediatrics Gender Care topic
No spam. Unsubscribe anytime.
Committee hears testimony on bill to restrict puberty blockers for minors
Summary
The Public Health and Community Health Committee held a hearing on Senate Bill 30, which would prohibit prescription of puberty-blocking medication for gender dysphoria in minors; medical witnesses and lawmakers discussed clinical exceptions, potential effects on standard care and whether bill language needs clarification. No vote was taken.
The Public Health and Community Health Committee on an announced date heard testimony on Senate Bill 30, a proposal by Senator Watson to prohibit prescription or administration of puberty-blocking medications for gender dysphoria in minors.
The bill’s sponsor, Senator Watson, described SB 30 as “a continuation of SB 140” and said the measure is intended to “clean[] up” earlier law by barring puberty blockers for gender dysphoria while preserving their use for other medical conditions the bill explicitly exempts. Watson told the committee that countries including Norway, Denmark, Finland and the United Kingdom have moved to restrict the drugs for minors and listed possible adverse effects Senate staff cited from clinical references, including decreased bone density and increased suicidality.
Dr. Michelle Zena, a pediatrician who said about 70 to 80 percent of her practice includes patients on the autism spectrum, testified she opposed use of puberty blockers for gender-related treatment in minors. “I have concerns about children making decisions that impact the rest of their life,” Zena said, adding that many children and adolescents, including those with autism, “struggle to label their own emotions” and may not provide informed consent for life‑changing interventions.
Other clinicians raised questions about whether the bill’s text, which preserves treatments for “medically verifiable disorders of sex development,” is sufficiently clear. Dr. Allen, a physician who identified several clinical scenarios to the committee, said, “I have some serious concerns about this bill with respect to it impeding standard treatments for established medical indications,” and pointed to conditions such as precocious puberty, prolactin‑secreting tumors (prolactinomas/galactorrhea) and androgen insensitivity as examples where similar medications are used for non‑gender‑related indications.
Several committee members pressed the sponsor about practical and legal effects. Members noted the bill would remove the grandfathering that was in place under SB 140 for youth already receiving blockers, and asked whether stopping blockers might cause psychological harm to youth who began treatment when it was legal. Senator Watson said the committee could refine language and would consult legal counsel and clinicians: “If you have better language, I’m happy to do it. This is a hearing only. We’re not voting on it today,” he said.
Witnesses cited national medical societies in discussion: the American Academy of Pediatrics, the American Psychiatric Association and the Endocrine Society were referenced by committee members as holding positions that differ from the bill’s premise. Witnesses and members also discussed whether FDA approval covers the pediatric use for gender‑related indications; a committee member observed that use in this context is commonly off‑label.
No motion or vote was taken; the sponsor and several members said they expect further drafting and consultation with endocrinologists and legislative counsel before the committee considers action.
The committee paused to attend other legislative business and agreed to reconvene for additional testimony, including from an endocrinologist who treats pediatric patients, at a later time.
